Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Fluorescein. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.59 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.59 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.54 |
| ▸ | FTO | Q9C0B1 | 8/20 | 0.97 |
| ▸ | MAPT | P10636 | 4/20 | 0.97 |
| ▸ | MEN1 | O00255 | 4/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.97 |
| ▸ | HTT | P42858 | 2/20 | 0.97 |
| ▸ | HPGD | P15428 | 2/20 | 0.97 |
| ▸ | RECQL | P46063 | 2/20 | 0.97 |
| ▸ | BLM | P54132 | 2/20 | 0.97 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.97 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.97 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.68 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluorescein SCHEMBL28866288 | 1.00 | FTO (0.97) | FTOMAPTMEN1KMT2ATDP1 | |
| Fluorescein SCHEMBL3293893 | 1.00 | FTO (0.97) | FTOMAPTMEN1KMT2ATDP1 | |
| Fluorescein SCHEMBL1425155 | 1.00 | FTO (0.97) | FTOMAPTMEN1KMT2ATDP1 | |
| Fluorescein SCHEMBL6691088 | 0.99 | FTO (0.94) | FTOMAPTMEN1KMT2ATDP1 | |
| Fluorescein SCHEMBL29388667 | 0.98 | FTO (1.00) | FTOMAPTMEN1KMT2ATDP1 | |
| Fluorescein SCHEMBL3645090 | 0.98 | FTO (1.00) | FTOMAPTMEN1KMT2ATDP1 | |
| Fluorescein SCHEMBL16533 | 0.98 | FTO (1.00) | FTOMAPTMEN1KMT2ATDP1 | |
| Fluorescein SCHEMBL30272223 | 0.98 | FTO (1.00) | FTOMAPTMEN1KMT2ATDP1 | |
| Fluorescein SCHEMBL29371199 | 0.98 | FTO (1.00) | FTOMAPTMEN1KMT2ATDP1 | |
| Fluorescein SCHEMBL17867543 | 0.97 | FTO (0.97) | FTOMAPTMEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112462055-B | Device and system for analyzing a sample, in particular blood, and method for using same | 上海宜晟生物科技有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-112462055-A | Device and system for analyzing a sample, in particular blood, and method for using same | ESSENLIX公司 | 2021-03-09 | — | — | CN | disclosed |
| CN-112400015-A | Method and system for performing heat-assisted biochemical reactions | 克里普托斯生物技术有限公司 | 2021-02-23 | — | — | CN | disclosed |
| CN-108700577-B | Device and system for analyzing a sample, in particular blood, and method for using same | ESSENLIX公司 | 2020-09-25 | — | — | CN | disclosed |
| EP-1958990-B1 | Colorant compounds | XEROX CORP (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-1961794-B1 | Phase change inks containing colorant compounds | XEROX CORP (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-1961793-B1 | Phase change inks containing colorant compounds | XEROX CORP (US) | 2013-03-13 | — | — | EP | disclosed |
| US-8163074-B2 | Phase change inks containing colorant compounds | XEROX CORPORATION (US) | 2012-04-24 | — | — | US | disclosed |
| EP-1956053-B1 | Colorant compounds | XEROX CORP (US) | 2011-03-23 | — | — | EP | disclosed |
| US-7910754-B2 | Colorant compounds | XEROX CORPORATION (US) | 2011-03-22 | — | — | US | disclosed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | disclosed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | disclosed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | disclosed |
| US-6860931-B2 | Phase change inks containing colorant compounds | XEROX CORPORATION (US) | 2005-03-01 | — | — | US | disclosed |
| US-20050016417-A1 | PHASE CHANGE INKS CONTAINING COLORANT COMPOUNDS | XEROX CORPORATION | 2005-01-27 | — | — | US | disclosed |
| US-20050011410-A1 | Colorant compounds | XEROX CORPORATION | 2005-01-20 | — | — | US | disclosed |
| US-20050011411-A1 | Colorant compounds | XEROX CORPORATION | 2005-01-20 | — | — | US | disclosed |
| EP-1493781-A1 | Rhodamine dye derivatives and their use for phase change inks | Xerox Corporation (US) | 2005-01-05 | — | — | EP | disclosed |
| US-20040261657-A1 | PHASE CHANGE INKS CONTAINING COLORANT COMPOUNDS | XEROX CORPORATION | 2004-12-30 | — | — | US | disclosed |
| US-6835238-B1 | Hot melts | XEROX CORPORATION | 2004-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050011411-A1 | Colorant compounds | CCNY, RB1, UQCRB | ESR1 538/4885ESR2 1226/4885HSP90AA1 4531/4885 |
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | ESR1 1511/4885ESR2 1600/4885HSP90AA1 4789/4885 |
| US-20050011410-A1 | Colorant compounds | CDYL, CDY1; CDY1B, RB1 | ESR1 802/4885ESR2 1289/4885HSP90AA1 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.